Synth supergroup

With a $53 million series A announced on Tuesday, Senti Biosciences Inc. is combining synthetic biology platform technologies from more than five institutions to build an immunotherapy pipeline and a partnering engine. The company believes its engineered biological circuits will generate adaptive cell and gene therapies with controlled responses to environmental cues.

Synthetic biology circuits incorporate two or more artificial components into cells, typically encoded in DNA, to carry out novel functions. Senti is developing circuits to control when, where and how potently cell and gene therapies exert their effects in vivo...